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The effect of dose on the antimalarial efficacy of artemether–
lumefantrine: a systematic review and pooled analysis of 
individual patient data
Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group*
Summary
Background—Artemether–lumefantrine is the most widely used artemisinin-based combination 
therapy for malaria, although treatment failures occur in some regions. We investigated the effect 
of dosing strategy on efficacy in a pooled analysis from trials done in a wide range of malaria-
endemic settings.
Methods—We searched PubMed for clinical trials that enrolled and treated patients with 
artemether–lumefantrine and were published from 1960 to December, 2012. We merged 
individual patient data from these trials by use of standardised methods. The primary endpoint was 
the PCR-adjusted risk of Plasmodium falciparum recrudescence by day 28. Secondary endpoints 
consisted of the PCR-adjusted risk of P falciparum recurrence by day 42, PCR-unadjusted risk of 
P falciparum recurrence by day 42, early parasite clearance, and gametocyte carriage. Risk factors 
for PCR-adjusted recrudescence were identified using Cox’s regression model with frailty shared 
across the study sites.
Findings—We included 61 studies done between January, 1998, and December, 2012, and 
included 14 327 patients in our analyses. The PCR-adjusted therapeutic efficacy was 97·6% (95% 
CI 97·4–97·9) at day 28 and 96·0% (95·6–96·5) at day 42. After controlling for age and 
parasitaemia, patients prescribed a higher dose of artemether had a lower risk of having 
parasitaemia on day 1 (adjusted odds ratio [OR] 0·92, 95% CI 0·86–0·99 for every 1 mg/kg 
increase in daily artemether dose; p=0·024), but not on day 2 (p=0·69) or day 3 (0·087). In Asia, 
children weighing 10–15 kg who received a total lumefantrine dose less than 60 mg/kg had the 
lowest PCR-adjusted efficacy (91·7%, 95% CI 86·5–96·9). In Africa, the risk of treatment failure 
was greatest in malnourished children aged 1–3 years (PCR-adjusted efficacy 94·3%, 95% CI 
92·3–96·3). A higher artemether dose was associated with a lower gametocyte presence within 14 
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days of treatment (adjusted OR 0·92, 95% CI 0·85–0·99; p=0·037 for every 1 mg/kg increase in 
total artemether dose).
Interpretation—The recommended dose of artemether–lumefantrine provides reliable efficacy 
in most patients with uncomplicated malaria. However, therapeutic efficacy was lowest in young 
children from Asia and young underweight children from Africa; a higher dose regimen should be 
assessed in these groups.
Funding—Bill & Melinda Gates Foundation.
Introduction
Artemisinin-based combination therapies are the first-line treatment for uncomplicated 
Plasmodium falciparum malaria in most malaria-endemic countries,1 and they have been 
advocated to counter the threat of antimalarial drug resistance by delaying its emergence and 
spread.2 As such, artemisinin-based combination therapies are a key component of malaria 
elimination efforts.3
The combination of artemether and lumefantrine was originally introduced as a four-dose 
regimen that proved to be efficacious in studies done in China,4 Africa,5 and India;6 
however, after detailed pharmacokinetic–pharmacodynamic assessment,7 the regimen was 
revised to comprise six doses, which was safe and effective even against multidrug-resistant 
parasites.8–10 In 2011, the six-dose regimen of artemether–lumefantrine (Coartem, Novartis, 
Basel, Switzerland) was the first artemisinin-based combination therapy to be prequalified 
by WHO.11 It is now registered in 86 countries and accounts for three-quarters of all 
artemisinin-based combination therapies used in clinical practice.1 In 2009, artemether–
lumefantrine dispersible tablets (Coartem Dispersible) were approved for use in young 
children,11 with more than 200 million treatments of this formulation dispensed since 
then.12
Although the six-dose artemether–lumefantrine regimen has high efficacy in most endemic 
areas, the usefulness of this combination is under threat from the emergence of parasites 
with reduced susceptibility to the artemisinins.13 Optimum dosing of antimalarial drug 
regimens is vital for containment of the spread of drug resistance; however, in clinical 
practice, pragmatic drug distribution results in dosing being based on weight or age banding, 
with patients at the margins of the bands having either lower or higher weight-adjusted 
doses than those in the middle of the bands.14 Young children are particularly vulnerable to 
suboptimum dosing because drugs are often given as tablets or fractions of tablets rather 
than paediatric formulations or suspensions.15 In this pooled analysis, we investigated the 
key determinants of the therapeutic efficacy of artemether–lumefantrine, with particular 
attention to the range of artemether and lumefantrine doses and the effect of these factors on 
clinical outcome.
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Methods
Search strategy and selection criteria
We did a systematic literature review in PubMed to identify all clinical trials published from 
1960 to December, 2012, selecting those that enrolled and treated patients with artemether–
lumefantrin (appendix). We selected studies for the meta-analysis if patients were treated 
with the six-dose artemether–lumefantrine regimen and were prospectively assessed for 
clinical efficacy against P falciparum (either alone or in mixed infections) for a minimum of 
28 days. Investigators were contacted by email and asked to share individual patient data 
and any unpublished study they might have. We included studies in the analysis if 
information was available on the dose given and on the age and weight of the patient, and if 
PCR genotyping was done to distinguish between recrudescence and new infections. 
Individual patient data were uploaded into the Worldwide Antimalarial Resistance Network 
(WWARN) secure repository, anonymised, and processed using standard methods described 
in the data management and statistical analysis plan.16
All data included in this analysis were obtained in accordance with ethical approvals from 
the country of origin. Ethical approval to undertake individual participant data meta-
analyses was granted by the Oxford Tropical Research Ethics Committee.
Procedures
We calculated the doses of artemether and lumefantrine administered from the individual 
number of daily tablets given to each patient. For studies in which the daily tablet count was 
not available, we did back calculations on the basis of the dosing plan presented in the study 
protocol, assuming correct adherence. Only patients who completed the six-dose treatment 
regimen over 3 days were included in the final analysis. Study sites were categorised as low, 
moderate, or high transmission settings on the basis of the transmission estimates obtained 
from the Malaria Atlas Project (appendix).17 In children younger than 5 years, we assessed 
nutritional status using the weight-for-age Z score, with standardised age-specific and sex-
specific growth references according to WHO 2006 recommendations.18 Patients were 
classified as being underweight for age if the weight-for-age Z score was less than −2. 
Scores outside the range −6 to 6 were treated as outliers.
Outcomes
The primary endpoint was the PCR-adjusted risk of P falciparum recrudescence by day 28. 
Secondary endpoints consisted of the PCR-adjusted risk of P falciparum recurrence by day 
42, PCR-unadjusted risk of P falciparum recurrence by day 42, early parasite clearance, and 
gametocyte carriage
Statistical analysis
We did all statistical analyses using R (version 2.14.0), on the basis of an a-priori statistical 
plan.19 We computed the incidence risks for the primary endpoint by survival analysis and 
compared Kaplan-Meier curves by the log-rank test after stratifying by study site. 
Definitions of outcome status and censoring are detailed in the WWARN clinical module 
data management and statistical analysis plan.16 The dose of lumefantrine was regarded 
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primarily as a risk factor for recrudescence because of its long half-life, whereas the dose of 
artemether was regarded as the primary determinant of the early parasitological response. 
We assessed risk factors associated with recrudescence with Cox’s proportional hazards 
model with shared frailty fitted on the combination of study and study sites to account for 
within-study clustering and any unreported heterogeneity.20 In the multivariable analysis, 
we forced known confounders (ie, age and parasitaemia) and dose (in mg/kg) into the model 
irrespective of their statistical significance. We categorised the origin of the studies into 
three groups: Africa, Asia, and South America. Other covariates significant at the 10% level 
in univariable analyses were added to the multivariable analyses and their inclusion was on 
the basis of a likelihood ratio test.21 We calculated the population-attributable risks 
associated with the risk factors on the basis of the prevalence and adjusted hazard ratio 
(HR).22 The proportions of patients with patent (microscopy-detected) parasitaemia were 
computed on days 1, 2, and 3 (parasite positivity rates), and gametocyte carriage was 
assessed as the proportion of patients with microscopy-detected P falciparum gametocytes 
(gametocyte positivity rates) on any given day during the follow-up period. Risk factors for 
parasite positivity rates and gametocyte positivity rates were analysed with mixed-effects 
logistic regression with sites (combination of study and study site) fitted as a random effect.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding authors had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
We identified 151 clinical trials of artemether–lumefantrine done between January, 1998, 
and December, 2012 (141 published, two in press, and eight unpublished), of which 115 
(76%) were randomised trials (figure 1; appendix). Individual patient data were available 
from 58 published studies (n=13 816 [69% of the targeted sample of 20 083]), two studies in 
press (n=302), and eight unpublished studies (n=1741). Seven studies (n=1119) did not meet 
the inclusion criteria and an additional 413 patients were excluded for protocol violations. 
Patients were followed up for 28 days in 34 studies (n=7460), for 42 days in 23 studies 
(n=6004), for 56 days in one study (n=359), and for 63 days or longer in three studies 
(n=504). Parasite genotyping was done in all of the studies, with at least three markers used 
in 34 (56%) studies.
Table 1 details the baseline characteristics of patients included in the analysis. The median 
age of patients was 4 years (range 1 month to 80 years), with 815 (6%) younger than 1 year 
and 7333 (51%) aged 1 year to younger than 5 years. Patients from Africa were significantly 
younger than those from either Asia or South America (p<0·0001) and had higher baseline 
parasitaemia (p=0·03; table 1). All the patients from Asia and South America were from low 
or moderate transmission settings, whereas only 6415 (54%) of 11 809 patients in Africa 
were from low or moderate transmission settings.
Overall, the median total dose of lumefantrine given was 68·6 mg/kg (IQR 57·6–80·0, range 
26·2–144·0) and that of artemether was 11·4 mg/kg (IQR 9·6–13·3, range 4·4–24·0). The 
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total dose of both components varied significantly between the different weight categories 
(p<0·0001; table 2). The proportion of patients who did not receive the therapeutic dose of 
lumefantrine varied across weight categories and regions (appendix). The lowest median 
lumefantrine doses were given to children aged 3–5 years (62·6 mg/kg, IQR 55·4–84·7) and 
to patients weighing more than 70 kg (38·4 mg/kg, IQR 36·0–40·6). Treatment 
administration was fully supervised in 11 069 (77%) of 14 327 patients, partly supervised in 
1936 (14%), and unsupervised in 1322 (9%).
Information regarding acute vomiting of drugs was available for 14 studies (n=5024), with 
221 (4%) of 5024 patients vomiting at least one dose of drug within 1 h of administration 
during the treatment course; this proportion was greatest (18 [11%] of 171) in infants 
younger than 1 year (appendix). After adjusting for age, fever at presentation, and baseline 
parasitaemia, the risk of acute vomiting was associated with increasing dose of lumefantrine, 
with every 5 mg/kg increase in lumefantrine dose associated with an 8·7% (95% CI 3·4–
14·2; p=0·001) increased risk of vomiting. There was no relation between the dose of 
lumefantrine and either late vomiting or diarrhoea in the first week.
The early therapeutic response was rapid. At 24 h after starting treatment, 5534 (60%) of 
9208 patients were parasite positive, falling to 910 (8%) of 12 055 by day 2 and 96 (1%) of 
12 829 by day 3; the age-stratified proportion of individuals who were parasite positive on 
these days are presented in the appendix. In multivariable analysis, baseline parasitaemia 
was the only independent predictor of parasite positivity on all days (table 3). Patients from 
Asia were at increased risk of parasite positivity on days 1 and 2, and those from South 
America were at increased risk on day 2 compared with patients from Africa (table 3). After 
controlling for baseline parasitaemia, region, and age category, a higher total daily dose of 
artemether was associated with a lower risk of parasite positivity on day 1 (p=0·024). There 
was no significant association between artemether dose and parasite positivity on days 2 or 3 
(table 3).
2310 (16%) of 14 327 patients had a recurrent parasitaemia detected during follow-up, and 
in 386 (17%) cases these could be confirmed as recrudescent infections by PCR. In patients 
who were followed up for 42 days, 139 (70%) of 200 recrudescences occurred before day 
28. The overall PCR-adjusted Kaplan-Meier therapeutic efficacy was 97·6% (95% CI 97·4–
97·9) at day 28 and 96·0% (95·6–96·5) at day 42. The overall risk of recrudescence was 
similar between patients from Asia and Africa (table 4). The PCR unadjusted and adjusted 
risk of recurrence for individual studies are presented in the appendix.
In univariable analyses, three risk factors on presentation were associated with a greater risk 
of recrudescence by day 28: age (p=0·001), bodyweight (p=0·001), and baseline 
parasitaemia (p=0·0002; table 4). The risk of recrudescence was similar between patients 
who were fully supervised and those who were partly or not supervised, and in patients who 
took the drug with or without a fatty meal (table 4). In multivariable analyses, baseline 
parasitaemia (p=0·0012) and young age (1–5 years; p=0·005) were the only independent risk 
factors associated with recrudescence by day 28 (table 4). We further investigated the 
relation between age and weight for children younger than 5 years. 679 (18%) of 3752 
children aged 1–3 years were underweight for their age. Children aged between 1 and 3 
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years who were underweight for age had an increased risk of recrudescence compared with 
those who were not (HR 1·56, 95% CI 1·04–2·43; p=0·033; figure 2), but there was no 
difference between groups for those aged 3–5 years (0·59, 0·31–1·14; p=0·12).
There was a significant interaction between regions and both lumefantrine dose 
(pinteraction=0·005) and baseline parasitaemia (pinteraction=0·012). Therefore, we generated 
separate models for Asia and Africa. We could not fit a model for patients from South 
America because of the small sample size. In Africa, the greatest risk of recrudescence was 
in underweight for age children between 1 and 3 years, among whom the PCR-adjusted 
efficacy was 94·3% (95% CI 92·3–96·3) compared with 96·9% (96·2–97·5) in those of 
similar age who were not underweight (adjusted HR 1·66, 95% CI 1·05–2·63; p=0·028; table 
5). For Asia, the corresponding adjusted HR was 1·07 (95% CI 0·17–6·78; p=0·94). The 
dose of lumefantrine was not associated with the risk of recrudescence in Africa, either 
overall (adjusted HR for every 5 mg/kg increase in dose 0·98, 95% CI 0·94–1·03; p=0·42) or 
in the subgroup of children who were underweight for their age (0·95, 0·81–1·10; p=0·47). 
By contrast, in Asia, the dose of lumefantrine was associated with the risk of recrudescence 
(adjusted HR 0·77, 95% CI 0·67–0·90; figure 3); efficacy was lowest in children weighing 
10–15 kg who received a total lumefantrine dose of less than 60 mg/kg (91·7%, 95% CI 
86·5–96·9). Patients who received less than 60 mg/kg (the WHO recommended lower 
bound) were at greater risk of recrudescence (adjusted HR 2·73, 95% CI 1·40–5·32; 
p=0·003), accounting for 41% of all treatment failures. Using the same model, we predicted 
that if patients from Asia with parasitaemia less than 267 000 parasites per μL received a 
minimum total lumefantrine dose of 60 mg/kg, then adequate cure would be achieved in at 
least 95% of cases (figure 3).
272 patients had patent gametocytaemia during follow-up. In 198 (73%) of these cases, 
gametocytes were present on or before day 14 of follow-up. In a multivariable model, after 
controlling for baseline gametocyte carriage, asexual parasite density, and age category, a 
higher artemether dose was associated with a lower gametocyte presence within 14 days of 
treatment (adjusted odds ratio 0·92, 95% CI 0·85–0·99; p=0·037 for every 1 mg/kg increase 
in total artemether dose).
Discussion
This pooled analysis of individual patient data comprises more than half of all clinical trials 
that have been published on the six-dose artemether–lumefantrine treatment regimen. Our 
findings confirm that artemether–lumefantrine treatment is an efficacious antimalarial 
regimen, resulting in a rapid therapeutic response. In more than 90% of patients, fever was 
resolved and peripheral parasitaemia was cleared within 48 h. Overall, the therapeutic 
efficacy of artemether–lumefantrine was 97·6% on day 28 and 96·0% on day 42, with only a 
slight effect of the total dose on these parameters. Patients who received a lower daily dose 
of artemether had an increased risk of parasitaemia on day 1 (8% for each 1 mg/kg decrease 
in daily artemether dose) and an increased risk of gametocyte carriage within 14 days (8% 
for each 1 mg/kg decrease in total artemether dose). Although high treatment efficacy was 
achieved in all age and weight categories, there were important regional differences. Patients 
from Asia had a slower initial therapeutic response compared with patients from Africa and 
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a greater risk of recrudescence. The dose of artemether–lumefantrine was an independent 
predictor of recrudescence in Asia but not Africa. These regional differences could represent 
either lower host immunity, in what are mostly low-transmission settings, or reduced 
parasite susceptibility to lumefantrine and artemether in the P falciparum parasites 
circulating in the Greater Mekong region.23,24 Our analysis shows that patients receiving 
less than 60 mg/kg of lumefantrine accounted for almost 42% of treatment failures in Asia, 
the effect being most noticeable in young children. Ensuring a lumefantrine dose above 60 
mg/kg would achieve greater than 95% cure in all patients, provided they presented with a 
parasitaemia less than 267 000 parasites per μL.
Since there was a significant interaction between regions and both lumefantrine dose and 
baseline parasitaemia, we generated separate models for Asia and Africa. In Africa, the risk 
of recrudescence was greatest in young children, especially those who were underweight for 
their age. The higher efficacy in older children and adults in Africa is probably a result of 
previous and repeated exposure to malaria, associated with the development of 
premunition.25,26 By contrast, infections in younger patients with lower host immunity are 
associated with higher baseline parasitaemia, increasing the risk of treatment failure,27 
especially in underweight children.28
The main determinant of artemether–lumefantrine clinical efficacy is the area under the 
curve of lumefantrine.29 The highly lipophilic lumefantrine is erratically absorbed, its 
bioavailability being affected by coadministration of food and the acute phase of the 
infection.29 The area under the curve for lumefantrine varies markedly with age and the 
nutritional status of the patient, with young children having a more rapid dose-normalised 
drug clearance compared with adults.30 To accommodate these differences, the dosing 
schedule of artemether–lumefantrine was modified in the early stages of drug development 
to ensure a higher mg/kg dose in young children.7 Our study shows the importance of this 
factor in this vulnerable group. Those who were underweight for their age were at increased 
risk of treatment failure. This effect could be due to either reduced drug absorption or an 
increased volume of distribution in malnourished children, both of which result in lower 
plasma drug concentrations.31
An increase in dose, particularly in children weighing 13–15 kg, might not necessarily result 
in higher blood concentrations since the absorption of lumefantrine saturates at 
recommended doses.32 Furthermore, an increase to the next dose band would result in these 
children receiving over 100 mg/kg of lumefantrine—a level that is associated with an 
increased risk of acute vomiting. A dispersible formulation of artemether–lumefantrine for 
administration in young children is now available, but this might not necessarily allow 
greater precision in achieving therapeutic blood concentrations, and its absorption kinetics 
and gastrointestinal tolerability at higher than recommended doses have yet to be well 
characterised. Administration of a 5-day (augmented dose) regimen might circumvent the 
dose-limited absorption and tolerability issues8 and increase the efficacy in high-risk 
patients, but effectiveness in clinical practice needs to be assessed.
Our study has several limitations. First, although the clinical data used in the analysis 
constitute almost 60% of the relevant published work on this treatment regimen, 44 studies 
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(n=6267) were not available, most of which (27 [61%]) were from Africa. However, there 
was no obvious selection bias between studies that were excluded from the analysis. Second, 
in only 4718 (33%) of 14 327 patients could drug doses be calculated from the actual 
number of tablets given; in the remainder of patients the total dose was extrapolated from 
the number of tablets to have been given per protocol, assuming complete adherence. 
However, when the method of dose calculation was included in the multivariable analysis 
the results remained unchanged. Third, ideally the weight-for-age Z scores to define 
nutritional status of the children should be calibrated to take regional variation into account. 
We controlled for these differences by stratifying the analysis on the basis of region (Asia 
and Africa), and the relation between nutritional status and treatment outcome remained. 
However, we were not able to differentiate between acute and chronic malnutrition, because 
data on patients’ height were not available.
In summary, the efficacy of artemether–lumefantrine remains excellent in most endemic 
areas. However, young children in the 10–15 kg weight band received a lower mg/kg total 
dose of artemether–lumefantrine, and this was associated with reduced efficacy, particularly 
in patients from Asia who presented with high parasitaemia and in malnourished patients 
from Africa. Further studies are warranted to optimise treatment strategies in these 
vulnerable populations. Although we found no evidence of temporal patterns in treatment 
failure, continued surveillance of artemether–lumefantrine efficacy is crucial to assure that 
appropriate responses to any decline can be implemented to prolong the clinical efficacy of 
this antimalarial drug in the long term.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the patients and all the staff who participated in these clinical trials at all the sites and the WWARN team 
for technical and administrative support.
WWARN AL Dose Impact Study Group
Australia N M Anstey, R N Price (Global and Tropical Health Division, Menzies School of 
Health Research and Charles Darwin University, Darwin, NT); T M E Davis (School of 
Medicine and Pharmacology, University of Western Australia, Crawley, WA); H A 
Karunajeewa, I Mueller (Infection and Immunity Division, Walter and Eliza Hall Institute, 
Melbourne, VIC); H A Karunajeewa (Division of Medicine, Western Health, VIC). Belgium 
U D’Alessandro (Unit of Malariology, Institute of Tropical Medicine, Antwerp). Bénin A 
Massougbodji (Centre d’Etudes et de Recherche sur le Paludisme Associé à la Grossesse et 
à l’Enfant, Faculté des Sciences de la Santé, Université d’Abomey-Calavi, Cotonou). 
Burkina Faso F Nikiema, J-B Ouédraogo, H Tinto, I Zongo (Institut de Recherche en 
Sciences de la Santé, Direction Régionale de l’Ouest, Bobo-Dioulasso); J-B Ouédraogo, H 
Tinto (Centre Muraz, Bobo-Dioulasso). Cameroon A Same-Ekobo (Faculté de Médecine et 
des Sciences Biomédicales, Centre Hospitalo-Universitaire de Yaoundé, Yaoundé). Côte 
d’Ivoire M Koné, H Menan, W Yavo (Department of Parasitology and Mycology, Faculty of 
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Pharmacy, University of Cocody, Abidjan); A O Touré (Malariology Department, Institut 
Pasteur de Côte d’Ivoire, Abidjan); W Yavo (Malaria Research and Control Center, National 
Institute of Public Health, Abidjan). Denmark P-E Kofoed (Department of Paediatrics, 
Kolding Hospital, Kolding). Ethiopia B H Alemayehu (International Center for AIDS Care 
and Treatment Programs, Addis Ababa); D Jima (Federal Ministry of Health, Addis Ababa). 
France E Baudin, E Espié, C Nabasumba, L Pinoges, B Schramm (Epicentre, Paris); M Cot, 
P Deloron, J-F Faucher (Institut de Recherche pour le Développement, Mother and Child 
Health in the Tropics Research Unit, Paris); M Cot, P Deloron, J-F Faucher (PRES 
Sorbonne Paris Cité, Université Paris Descartes, Paris); J-F Faucher (Department of 
Infectious Diseases, Besançon University Medical Center, Besançon); J-P Guthmann 
(Département des Maladies Infectieuses, Institut de Veille Sanitaire, Saint Maurice). Gabon 
B Lell (Centre de Recherches Médicales de Lambaréné, Lambaréné). Germany S Borrmann 
(Department of Microbiology, Magdeburg University School of Medicine, Magdeburg); B 
Lell (Institute for Tropical Medicine, University of Tubingen, Tubingen). Ghana G O Adjei 
(Centre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical 
School, Accra). Guinea-Bissau P-E Kofoed, J Ursing (Projecto de Saúde de Bandim, 
Bissau). Indonesia E Tjitra (National Institute of Health Research and Development, 
Ministry of Health, Jakarta). Kenya S Borrmann, K Marsh, J Peshu (Kenya Medical 
Research Institute and Wellcome Trust Research Programme, Kilifi); E Juma (Kenya 
Medical Research Institute, Nairobi); B R Ogutu (Kenya Medical Research Institute and 
United States Army Medical Research Unit, Kisumu); S A Omar, P Sawa (Human Health 
Division, International Centre for Insect Physiology and Ecology, Mbita Point); A O 
Talisuna (WWARN-East Africa Regional Centre, Nairobi); A O Talisuna (University of 
Oxford, KEMRI, and Wellcome Trust Research Programme, Nairobi). Laos M 
Khanthavong (Centre of Malariology, Parasitology and Entomology, Vientiane); M 
Mayxay, P N Newton (Wellcome Trust-Mahosot Hospital-Oxford University Tropical 
Medicine Research Collaboration, Mahosot Hospital, Vientiane); M Mayxay (Faculty of 
Medical Science, National University of Laos, Vientiane). Madagascar P Piola (Institut 
Pasteur de Madagascar, Antananarivo). Mali A A Djimdé, O K Doumbo, B Fofana, I Sagara 
(Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, 
Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Bamako, Bamako). 
Mozambique Q Bassat, R González, C Menéndez (Centro de Investigacao em Saude de 
Manhica, Manhica). Myanmar (Burma) F Smithuis (Myanmar Oxford Clinical Research 
Unit, Yangon), F Smithuis (Myanmar and Medical Action Myanmar, Yangon). Netherlands 
T Bousema (Department of Medical Microbiology, Radboud University Nijmegen Medical 
Centre, Njimegen); P A Kager, P F Mens (Centre for Infection and Immunity Amsterdam 
[CINEMA], Division of Infectious Diseases, Tropical Medicine and AIDS, Academic 
Medical Centre, Amsterdam); P F Mens, H D F H Schallig (Royal Tropical Institute, KIT 
Biomedical Research, Amsterdam); I Van den Broek (Centre for Infectious Disease Control, 
National Institute for Public Health and the Environment, Bilthoven); M Van Vugt (Division 
of Infectious Diseases, Center for Tropical Medicine and Travel Medicine, Academic 
Medical Center, University of Amsterdam). Niger M L Ibrahim (Centre de Recherche 
Médicale et Sanitaire, Niamey). Nigeria C O Falade (College of Medicine, University of 
Ibadan, Ibadan); M Meremikwu (Department of Paediatrics, University of Calabar, 
Calabar); M Meremikwu (Institute of Tropical Diseases Research and Prevention, Calabar). 
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Portugal J P Gil (Drug Resistance and Pharmacogenetics, Center for Biodiversity, 
Functional and Integrative Genomics, Faculdade de Ciências, Universidade de Lisboa, 
Lisbon). Rwanda C Karema (Malaria and Other Parasitic Diseases Division-RBC, Ministry 
of Health, Kigali). Senegal M S Ba, B Faye, O Faye, O Gaye, J-L Ndiaye, M Pene, D Sow, 
K Sylla, R C K Tine (Department of Parasitology and Mycology, Faculty of Medicine, 
University Cheikh Anta Diop, Dakar); L K Penali (WWARN-West Africa Regional Centre, 
Dakar). South Africa K I Barnes, L J Workman (WWARN, Pharmacology Module, Cape 
Town); K I Barnes, L J Workman (Division of Clinical Pharmacology, Department of 
Medicine, University of Cape Town, Cape Town). Spain Q Bassat, R González, C 
Menéndez, I Mueller (Centre de Recerca en Salut Internacional de Barcelona, Barcelona); A 
Lima (Médecins Sans Frontières—Operational Centre Barcelona-Athens, Barcelona). Sudan 
I Adam (Faculty of Medicine, University of Khartoum, Khartoum); N B Gadalla 
(Department of Epidemiology, Tropical Medicine Research Institute, National Centre for 
Research, Khartoum); E F M Malik (Federal Ministry of Health, Khartoum). Sweden A 
Björkman (Infectious Diseases Unit, Department of Medicine, Karolinska University 
Hospital, Karolinska Institutet, Stockholm); J P Gil (Department of Physiology and 
Pharmacology, Drug Resistance Unit, Section of Pharmacogenetics, Karolinska Institutet, 
Stockholm); A Mårtensson, B E Ngasala, J Ursing (Malaria Research, Infectious Disease 
Unit, Department of Medicine Solna, Karolinska Institutet); A Mårtensson (Department of 
Public Health Sciences, Division of Global Health, Karolinska Institutet, Stockholm); L 
Rombo (Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, 
Karolinska University Hospital, Karolinska Institutet); L Rombo (Department of Infectious 
Diseases, Eskilstuna); L Rombo (Centre for Clinical Research, Sörmland County Council, 
Sörmland). Switzerland P Aliu (Novartis Pharma AG, Basel); S Duparc (Medicine for 
Malaria Venture, Geneva); S Filler (The Global Fund to Fight AIDS, Tuberculosis and 
Malaria, Geneva); B Genton (Department of Epidemiology and Public Health, Swiss 
Tropical and Public Health Institute, Basel); B Genton (Division of Infectious Diseases and 
Department of Ambulatory Care and Community Medicine, University Hospital, Lausanne); 
E M Hodel (Swiss Tropical and Public Health Institute, Basel); P Olliaro (UNICEF, UNDP, 
World Bank, and WHO Special Programme for Research and Training in Tropical Diseases, 
Geneva). Tanzania S Abdulla (Ifakara Health Institute, Dar es Salaam); E Kamugisha 
(Catholic University of Health and Allied Sciences, Mwanza); B E Ngasala, Z Premji 
(Department of Parasitology, Muhimbili University of Health and Allied Sciences, Dar es 
Salaam); S A Shekalaghe (Kilimanjaro Clinical Medical Research Institite, Kilimanjaro 
Christian Medical Centre, Moshi); S A Shekalaghe (Ifakara Health Institute, Bagamoyo). 
Thailand E A Ashley, V I Carrara, R McGready, F Nosten (Shoklo Malaria Research Unit, 
Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol 
University, Mae Sot); E A Ashley, A M Faiz, S J Lee, N J White (Faculty of Tropical 
Medicine, Mahidol University, Bangkok); V I Carrara, A M Dondorp (Mahidol Oxford 
University Research Unit, Mahidol University, Bangkok); J J Smith (WWARN-Asia 
Regional Centre, Bangkok). The Gambia U D’Alessandro (Medical Research Council Unit, 
Fajara); J Tarning (Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical 
Medicine, Mahidol University, Bangkok). Uganda J Achan, H Bukirwa, A Yeka (Uganda 
Malaria Surveillance Project, Kampala); E Arinaitwe, S G Staedke (Infectious Diseases 
Research Collaboration, Kampala); M R Kamya (College of Health Sciences, Makerere 
Page 10
Lancet Infect Dis. Author manuscript; available in PMC 2015 November 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
University, Kampala); F Kironde (Department of Biochemistry, Makerere University, 
Kampala); C Nabasumba (Faculty of Medicine, Mbarara University of Science and 
Technology, Mbarara). UK T Bousema, C J Drakeley, N B Gadalla, M Oguike, C J 
Sutherland (Immunology and Infection Department, London School of Hygiene and 
Tropical Medicine, London); F Checchi (Humanitarian Department, Save the Children, 
London); P Dahal, J A Flegg, P J Guerin, C Moreira, P N Newton, C Nsanzabana, R N 
Price, C H Sibley, K Stepniewska, J Tarning (Worldwide Antimalarial Resistance Network, 
Oxford); P Dahal, A M Dondorp, J A Flegg, P J Guerin, S J Lee, K Marsh, R McGready, C 
Moreira, P N Newton, F Nosten, C Nsanzabana, P Olliaro, R N Price, J Tarning, N J White 
(Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical 
Medicine, University of Oxford, Oxford); P W Gething, S I Hay (Spatial Ecology and 
Epidemiology Group, Department of Zoology, University of Oxford, Oxford); B Greenwood 
(Department of Diseases Control, London School of Hygiene and Tropical Medicine, 
London); E M Hodel, S A Ward (Parasitology Department, Liverpool School of Tropical 
Medicine, Liverpool); S G Staedke (Department of Clinical Research, Faculty of Infectious 
and Tropical Diseases, London School of Hygiene and Tropical Medicine, London); I Van 
den Broek (Médecins sans Frontières, London); P A Winstanley (Warwick Medical School, 
University of Warwick, Coventry). USA G Dorsey, B Greenhouse, P J Rosenthal 
(Department of Medicine, University of California San Francisco, San Francisco, CA); N B 
Gadalla (National Institute of Allergy and Infectious Diseases, Rockville, MD); J P Gil (The 
Harpur College of Arts and Sciences, Binghamton University, The State University of New 
York, Binghamton, NY); A Grivoyannis (Division of Emergency Medicine, University of 
Washington, Seattle, WA); K Hamed (Novartis, East Hanover, NJ); J Hwang, P S Kachur 
(US Centers for Disease Control and Prevention, Atlanta, GA); J Hwang (Global Health 
Group, University of California San Francisco, San Francisco, CA); C H Sibley (Department 
of Genome Sciences, University of Washington, Seattle, WA). Zambia M Nambozi 
(Tropical Diseases Research Centre, Ndola, Zambia).
Contributors
SA, JA, IA, GOA, BHA, PA, NMA, EA, EAA, MSB, KIB, QB, EB, AB, SB, TB, HB, VIC, 
FC, MC, UD’A, TMED, PDe, AAD, AMD, GD, OKD, CJD, SD, EE, AMF, COF, J-FF, 
BFa, OF, SF, BFo, NBG, OG, BGe, JPGi, RG, BryGr BriGr, AG, PJG, J-PGu, KH, EMH, 
JH, DJ, EJ, PSK, PAK, EK, MRK, CK, HAK, MKh, FK P-EK, MKo, IML, SJL, BL, AL, 
EMM, KM, AMar, AMas, MMa, RMG, HM, CMe, PFM, MMe, IM, CNa, MN, J-LN, PNN, 
BEN, FNi, FNo, MO, BRO, PO, SAO, J-BO, LKP, MP, JP, LP, PP, ZP, RNP, LR, PJR, IS, 
AS-E, PS, HDFHS, BS, SAS, CHS, FS, DS, SGS, CJS, KSy, AOT, JT, ET, RCKT, HT, 
OAT, JU, IVDb, MVV, SAW, NJW, PAW, WY, AY, and IZ conceived and designed the 
experiments. SA, JA, IA, GOA, BHA, PA, NMA, EA, EAA, MSB, KIB, QB, EB, AB, SB, 
TB, HB, VIC, FC, MC, UD’A, TMED, PDe, AAD, AMD, GD, OKD, CJD, SD, EE, AMF, 
COF, J-FF, BFa, OF, SF, JAF, BFo, NBG, OG, BGe, PWG, JPGi, RG, BryGr, BriGr, AG, 
PJG, J-PGu, KH, SIH, EMH, JH, DJ, EJ, PSK, PAK, EK, MRK, CK, HAK, MKh, FK, P-
EK, MKo, IML, SJL, BL, AL, EMM, KM, AMar, AMas, MMa, RMG, HM, CMe, PFM, 
MMe, IM, CNa, MN, J-LN, PNN, BEN, FNi, FNo, MO, BRO, PO, SAO, J-BO, LKP, MP, 
JP, LP, PP, ZP, RNP, LR, PJR, IS, A-SE, PS, HDFHS, BS, SAS, FS, DS, SGS, CJS, KSy, 
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AOT, JT, ET, RCKT, HT, OAT, JU, IVdB, MVV, SAW, NJW, PAW, WY, AY, and IZ did 
the experiments. PDa, PJG, CMo, CNs, RNP, and KSt analysed the pooled individual 
patient data. JAF, PWG, SIH, and LJW contributed reagents, materials, or analysis 
instruments. PDa, PJG, CNs, and RNP wrote the first draft of the manuscript. All study 
group members contributed to the writing of the manuscript. SA, JA, IA, GOA, BHA, PA, 
NMA, EA, EAA, MSB, KIB, QB, EB, AB, SB, TB, HB, VIC, FC, MC, UDA, TMED, PDe, 
AAD, AMD, GD, OKD, CJD, SD, EE, AMF, COF, J-FF, BFa, OF, SF, JAF, BFo, NBG, 
OG, BGe, PWG, JPGi, RG, BryGr, BriGr, AG, PJG, J-PGu, KH, SIH, EMH, JH, DJ, EJ, 
PSK, PAK, EK, MRK, CK, HAK, MKh, FK, P-EK, MKo, IML, SJL, BL, AL, EMM, KM, 
AMar, AMas, MMa, RMG, HM, CMe, PFM, MMe, IM, CNa, MN, J-LN, PNN, BEN, FNi, 
FNo, AO, MO, BRO, PO, SAO, JBO, LKP, MP, JP, LP, PP, ZP, RNP, LR, PJR, IS, AS-E, 
PS, HDFHS, BS, SAS, FS, DS, SGS, CJS, KSy, AOT, JT, ET, RCKT, HT, OAT, JU, IVdB, 
MVV, SAW, NJW, PAW, WY, AY, and IZ enrolled patients.
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Figure 1. Study flowchart
WWARN=Worldwide Antimalarial Resistance Network.
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Figure 2. Cumulative risk of PCR-confirmed recrudescence by day 28 in children aged 1–5 years
Error bars are 95% CIs.
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Figure 3. Risk of recrudescence by day 28 in Africa and Asia
The predicted risk of recrudescence by day 28 for a given enrolment parasitaemia and total 
lumefantrine dose in Africa and Asia. The risks were estimated using the coefficients for 
parasitaemia and lumefantrine dose from a Cox’s model containing age, dose, and baseline 
parasitaemia for Africa. For Asia, the model contained dose and baseline parasitaemia. We 
assumed zero study effects. The horizontal line represents the 5% treatment failure rate 
threshold from WHO that should be used to assess if a new drug can be introduced for 
treatment of uncomplicated malaria. The vertical line is the parasitaemia of 100 000 per μL, 
a threshold used in the multivariable models for calculating the population-attributable risk 
estimates.
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Table 1
Demographics and baseline characteristics
Asia (n=2359) Africa (n=11 809) South America
(n=159)*
Overall (n=14 327)
Study period 1998–2010 2002–12 2007–08 1998–2012
Sex†
 Female 929 (39%) 5538 (47%) 63 (40%) 6530 (46%)
 Male 1430 (61%) 5973 (51%) 96 (60%) 7499 (52%)
Age, years
 Median (range) 16·0 (0·5–80·0) 3·5 (0·0–77·0) 23·0 (12·0–56·0) 4·0 (0·0–80·0)
 <1 6 (<1%) 809 (7%) 0 815 (6%)
 1 to <5 373 (16%) 6960 (59%) 0 7333 (51%)
 5 to <12 503 (21%) 2477 (21%) 0 2980 (21%)
 ≥12 1477 (63%) 1563 (13%) 159 (100%) 3199 (22%)
Weight, kg
 Median (range) 41·0 (6·0–88·0) 13·7 (5·0–102·0) 64·0 (30·0–110·0) 15·0 (5·0–110·0)
 5 to <10 61 (3%) 2013 (17%) 0 2074 (14%)
 10 to <15 334 (14%) 4623 (39%) 0 4957 (35%)
 15 to <25 404 (17%) 2992 (25%) 0 3396 (24%)
 25 to <35 206 (9%) 753 (6%) 4 (3%) 963 (7%)
 35 to <70 1341 (57%) 1278 (11%) 105 (66%) 2724 (19%)
 ≥70 13 (1%) 150 (1%) 50 (31%) 213 (1%)
Treatment supervision‡
 Full 1824 (77%) 9086 (77%) 159 (100%) 11 069 (77%)
 Partial 373 (16%) 1563 (13%) 0 1936 (14%)
 Unsupervised 162 (7%) 1160 (10%) 0 1322 (9%)
Treatment coadministration
 With fatty meal 656 (28%) 5635 (48%) 159 (100%) 6450 (45%)
 Without fatty meal 0 1191 (10%) 0 1191 (8%)
 Advised to consume with fat 820 (35%) 1326 (11%) 0 2146 (15%)
 Not stated 883 (37%) 3657 (31%) 0 4540 (32%)
Drug tradename
 Coartem (Novartis) 2359 (100%) 11 126 (94%) 159 (100%) 13 644 (95%)
 Coartem dispersible (Novartis) 0 431 (4%) 0 431 (3%)
 Co-artesiane (Dafra, Turnhout, Belgium) 0 134 (1%) 0 134 (1%)
 Atrin (LIC Pharmaceuticals, Abidjan, Côte 
d’Ivoire)
0 118 (1%) 0 118 (1%)
Enrolment clinical variables
 Parasitaemia, parasites per μL 9559 (13–450 440) 21 360 (16–420 360) 4241 (1008–44 744) 19 921 (13–450 440)
 Parasitaemia >100 000/μL 226 (10%) 1131 (10%) 0 1357 (9%)
 Mixed infection with Plasmodium vivax 134 (6%) 0 0 134 (1%)
 Haemoglobin, g/L 114 (25·8) 101 (21·2) NR 104 (22·9)
 Anaemic, haemoglobin <100 g/L 600/2179 (28%) 4030/8287 (49%) NR 4630/10 466 (44%)
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Asia (n=2359) Africa (n=11 809) South America
(n=159)*
Overall (n=14 327)
 Gametocytes present 128/1118 (11%) 541/7850 (7%) 10 (6%) 679/9127 (7%)
 Fever, temperature >37·5°C 1199/2195 (55%) 6973/10 854 (64%) 103 (65%) 8275/13 208 (63%)
 Children underweight for age§ 173/471 (37%) 1352/7825 (17%) NR 1525/8296 (18%)
Data are number (%), median (IQR), or mean (SD), unless otherwise specified. Some percentages do not add up to 100 because of rounding. 
NR=not reported.
*
Data from one study done in Colombia.
†
Data were not available for 298 patients from Africa.
‡
Patients with only morning daily doses supervised and evening doses taken at home with no supervision were classified as partly supervised. 
Patients were classified as unsupervised if all six doses were unobserved or if the first dose was observed at the clinic with remaining five doses 
unobserved.
§
Defined using a weight-for-age score <−2 in children <5 years of age. Scores outside the range −6 to 6 were treated as outliers.
Lancet Infect Dis. Author manuscript; available in PMC 2015 November 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Page 19
Table 2
Total lumefantrine and artemether doses
Number Lumefantrine dose, mg/kg Artemether dose, mg/kg
Median (IQR) Range Median (IQR) Range
Overall 14 327 68·6 (57·6–80·0) 26·2–144·0 11·4 (9·6–13·3) 4·4–24·0
Age category, years
 <1 815 90·0 (81·8–102·9) 40–144 15·0 (13·6–17·1) 6·7–24
 1 to <5 7333 68·6 (60·0–80·0) 37·9–144 11·4 (10–13·3) 6·3–24
 5 to <12 2980 73·8 (65·5–83·1) 32–120 12·3 (10·9–13·8) 5·3–20
 ≥12 3199 57·6 (49·7–65·5) 26·2–91·9 9·6 (8·3–10·9) 4·4–15·3
Weight category, kg
 5 to <10 2074 85·7 (80·0–94·7) 37·9–144·0 14·3 (13·3–15·8) 6·3–24·0
 10 to <15 4957 60·0 (55·4–67·3) 42·9–100·7 10·0 (9·2–11·2) 7·1–16·8
 15 to <25 3396 80·0 (72·0–90·0) 39·6–105·0 13·3 (12·0–15·0) 6·6–17·5
 25 to <35 963 74·5 (68·4–83·1) 42·4–96·9 12·4 (11·4–13·8) 7·1–16·2
 35 to <70 2724 57·0 (50·5–64·0) 30·9–82·3 9·5 (8·4–10·7) 5·1–13·7
 ≥70 213 38·4 (36·0–40·6) 26·2–41·1 6·4 (6·0–6·8) 4·4–6·9
Region
 Asia 2359 61·3 (55·4–72·0) 30·9–120·0 10·2 (9·2–12·0) 5·1–20·0
 Africa 11 809 71·3 (60·0–80·9) 28·2–144·0 11·9 (10·0–13·5) 4·7–24·0
 South America 159 45·0 (40·6–53·3) 26·2–82·3 7·5 (6·8–8·9) 4·4–13·7
Drug tradename
 Artrin 118 74·8 (60–90·0) 51·4–120·0 12·5 (10–15·0) 8·6–20·0
 Co-artesiane 134 71·1 (69·4–74·8) 60·7–79·2 11·8 (11·6–12·5) 10·1–13·2
 Coartem 14 075 68·4 (57·6–80·0) 26·2–144·0 11·4 (9·6–13·3) 4·4–24·0
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Table 4
Risk factors for PCR-confirmed recrudescence at day 28
Total N (n)* Univariable analyses Multivariable analyses † PAR calculations ‡
Crude HR 
(95% CI)
p value Adjusted HR 
(95% CI)
p value Frequency§ PAR
Age, every 1-year increase 14 139 (304) 0·96 (0·94–0·99) 0·001 · · · · · · · ·
Bodyweight, every 1 kg increase 14 139 (304) 0·98 (0·97–0·99) 0·001 · · · · · · · ·
Lumefantrine dose, every 5 mg/kg
increase
14 139 (304) 0·98 (0·95–1·02) 0·380 0·98 (0·94–1·02) 0·380 27·46% 6·30%
Enrolment clinical variables
 Parasitaemia, parasites per μL 
every
ten-times increase
14 139 (304) 1·47 (1·2–1·81) 0·0002 1·41 (1·15–1·74) 0·0012 9·51% 4·01%
 Fever, temperature >37·5°C 13 024 (290) 1·09 (0·85–1·41) 0·500 · · · · · · · ·
 Haemoglobin, every 10 g/L 
increase
10 303 (221) 0·95 (0·88–1·01) 0·100 · · · · · · · ·
 Anaemia, haemoglobin <100 g/L 10 303 (221) 1·24 (0·93–1·65) 0·150 · · · · · · · ·
 Gametocytes present 9008 (198) 1·01 (0·62–1·65) 0·970 · · · · · · · ·
Sex
 Female 6448 (143) Reference · · · · · · · · · ·
 Male 7393 (156) 0·95 (0·76–1·20) 0·690 · · · · · · · ·
Age category, years
 ≥12 3160 (34) Reference · · · · · · · · · ·
 <1 809 (21) 1·73 (0·92–3·29) 0·091 1·78 (0·89–3·55) 0·100 5·72% 4·76%
 1 to <5 7231 (204) 2·17 (1·35–3·47) 0·001 2·00 (1·23–3·23) 0·005 51·14% 37·92%
 5 to <12 2939 (45) 1·33 (0·81–2·18) 0·260 1·27 (0·76–2·12) 0·360 20·79% 7·96%
Transmission setting
 Low 3432 (60) Reference · · · · · · · · · ·
 High 5336 (160) 1·75 (0·92–3·33) 0·086 · · · · · · · ·
 Moderate 5371 (84) 1·13 (0·58–2·23) 0·720 · · · · · · · ·
Region
 Africa 11 674 (260) Reference · · · · · · · · · ·
 Asia 2306 (43) 0·81 (0·34–1·90) 0·630 · · · · · · · ·
 South America 159 (1) 0·25 (0·02–4·16) 0·330 · · · · · · · ·
Treatment supervision
 Full 10 929 (232) Reference · · · · · · · · · ·
 Partial 1909 (51) 1·40 (0·76–2·59) 0·280 · · · · · · · ·
 Unsupervised 1301 (21) 1·31 (0·52–3·28) 0·570 · · · · · · · ·
Coadministration with fat
 With fatty meal 6346 (142) Reference · · · · · · · · · ·
 Without fatty meal 1181 (23) 0·95 (0·34–2·67) 0·920 · · · · · · · ·
 Advised with fatty meal 2120 (39) 0·98 (0·40–2·41) 0·960 · · · · · · · ·
Dose calculation method
 Per protocol 9473 (231) Reference · · · · · · · · · ·
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Total N (n)* Univariable analyses Multivariable analyses † PAR calculations ‡
Crude HR 
(95% CI)
p value Adjusted HR 
(95% CI)
p value Frequency§ PAR
 Tablet counts 4666 (73) 0·73 (0·43–1·24) 0·250 · · · · · · · ·
Drug tradename
 Coartem 13 891 (296) Reference · · · · · · · · · ·
 Generic artemether–lumefantrine 248 (8) 1·12 (0·42–2·99) 0·820 · · · · · · · ·
HR=hazard ratio. PAR=population-attributable risk.
*Number of patients (number with recrudescence by day 28).
†
The assumption of proportional hazard held for the model (p=0·47 for global test) and for all the individual covariates in the multivariable model 
(p>0·05). The variance of random eff ect was 0·95. The likelihood ratio test was not significant for bodyweight (p=0·19), haemoglobin (p=0·29), 
and transmission (p=0·53) in the presence of mg/kg dose, parasitaemia, and age category; thus, these were dropped from the multivariable analysis.
‡Overall PAR for model: 51·1%. Cumulative PAR for parasitaemia >100 000 parasites per μL and age 1 to <5 years: 40·4%.
§
The proportion of patients with the risk factor. Continuous covariates were categorised as follows: baseline parasitaemia at 100 000 parasites per 
μL and mg/kg lumefantrine dose at 60 mg/kg (lower bound of WHO therapeutic range). The adjusted HR used for estimating the PARs (obtained 
from the categorised model) were 1·44 for baseline parasitaemia, 1·24 for lumefantrine dose <60 mg/kg, 1·87 for age <1 year, 2·19 for age 1–5 
years, and 1·42 for age 5–12 years.
Lancet Infect Dis. Author manuscript; available in PMC 2015 November 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Page 23
Ta
bl
e 
5
M
ul
tiv
ar
ia
bl
e 
m
od
el
s f
or
 r
isk
 fo
r 
re
cr
ud
es
ce
nc
e 
in
 p
at
ie
nt
s f
ro
m
 A
fr
ic
a 
an
d 
A
sia
 b
y 
da
y 
28
A
fr
ic
a 
*
A
sia
 *
To
ta
l N
 (n
)†
A
dju
ste
d H
R 
(95
%
 C
I)
p 
va
lu
e
Fr
eq
ue
nc
y
PA
R
To
ta
l N
 (n
)†
A
dju
ste
d H
R 
(95
%
 C
I)
p 
va
lu
e
Fr
eq
ue
nc
y
PA
R
Lu
m
ef
an
tri
ne
 d
os
e 
<6
0 
m
g/
kg
11
 5
47
 (2
55
)
1·
20
 (0
·85
–1
·68
)
0·
30
24
·1
%
4·
5%
23
00
 (4
3)
2·
73
 (1
·40
–5
·32
)
0·
00
3
41
·0
%
41
·5
%
B
as
el
in
e 
pa
ra
sit
ae
m
ia
,
>
10
0 
00
0 
pa
ra
sit
es
 p
er
 μ
L‡
11
 5
47
 (2
55
)
1·
44
 (0
·99
–2
·1)
0·
05
4
9·
6%
4·
1%
23
00
 (4
3)
1·
76
 (0
·78
–3
·97
)
0·
18
9·
8%
6·
9%
A
ge
 c
at
eg
or
y,
 k
g
 
≥1
2,
 re
fe
re
nc
e
15
51
 (1
0)
1
·
 
·
·
 
·
·
 
·
14
50
 (2
3)
1
·
 
·
·
 
·
·
 
·
 
<
1§
80
3 
(21
)
2·
20
 (0
·94
–5
·17
)
0·
07
1
7·
0%
7·
7%
·
 
·
·
 
·
·
 
·
·
 
·
·
 
·
 
1 
to
 <
3 
U
W
A
64
1 
(31
)
4·
05
 (1
·78
–9
·18
)
0·
00
1
5·
6%
14
·5
%
38
 (2
)
3·
97
 (0
·87
–1
8·1
6)
0·
07
5
1·
7%
4·
7%
 
1 
to
 <
3 
no
t U
W
A
29
86
 (8
4)
2·
52
 (1
·19
–5
·34
)
0·
01
6
25
·9
%
28
·2
%
87
 (3
)
3·
38
 (0
·92
–1
2·4
3)
0·
06
7
3·
8%
8·
2%
 
3 
to
 <
5
31
13
 (7
3)
2·
18
 (1
·04
–4
·56
)
0·
03
8
27
·0
%
24
·2
%
23
9 
(6)
1·
73
 (0
·66
–4
·51
)
0·
27
10
·4
%
7·
0%
 
5 
to
 <
12
24
53
 (3
6)
1·
67
 (0
·77
–3
·59
)
0·
19
21
·2
%
12
·4
%
48
6 
(9)
1·
50
 (0
·65
–3
·46
)
0·
34
21
·1
%
9·
6%
H
R
=h
az
ar
d 
ra
tio
. P
A
R=
po
pu
la
tio
n-
at
tri
bu
ta
bl
e 
ris
k.
 U
W
A
=u
nd
er
w
ei
gh
t f
or
 a
ge
.
*
Th
e 
as
su
m
pt
io
n 
of
 p
ro
po
rti
on
al
 h
az
ar
ds
 w
as
 m
et
 fo
r e
ac
h 
m
od
el
 (p
=0
·54
 fo
r A
fri
ca
 an
d p
=0
·18
 fo
r A
sia
 by
 th
e S
ch
oe
nfe
ld’
s t
est
). T
he
 ov
era
ll P
AR
 w
as 
66
·5%
 fo
r A
fri
ca
 an
d 5
9·9
% 
for
 A
sia
.
† N
um
be
r o
f p
at
ie
nt
s (
nu
mb
er 
wi
th 
rec
rud
esc
en
ce
 by
 da
y 2
8).
‡ A
dju
ste
d H
Rs
 w
ere
 1·
31
 (9
5%
 C
I 1
·03
–1
·66
) a
nd
 2·
2 (
1·3
7–
3·5
4) 
for
 ev
ery
 in
cre
ase
 of
 te
n t
im
es.
§ O
nl
y 
six
 p
at
ie
nt
s a
ge
d 
<1
 y
ea
r i
n 
A
sia
 h
ad
 n
o 
PC
R-
co
nf
irm
ed
 fa
ilu
re
. H
R 
co
ul
d 
no
t b
e 
es
tim
at
ed
 fo
r t
hi
s g
ro
up
.
Lancet Infect Dis. Author manuscript; available in PMC 2015 November 04.
